Pars plana vitrectomy with internal limiting membrane flap versus pars plana vitrectomy with conventional internal limiting membrane peeling for large macular hole.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
07 08 2023
Historique:
pmc-release: 07 08 2024
medline: 8 8 2023
pubmed: 7 8 2023
entrez: 7 8 2023
Statut: epublish

Résumé

Macular hole (MH) is a full-thickness defect in the central portion of the retina that causes loss of central vision. According to the usual definition, a large MH has a diameter greater than 400 µm at the narrowest point. For closure of MH, there is evidence that pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling achieves better anatomical outcomes than standard PPV. PPV with ILM peeling is currently the standard of care for MH management; however, the failure rate of this technique is higher for large MHs than for smaller MHs. Some studies have shown that the inverted ILM flap technique is superior to conventional ILM peeling for the management of large MHs. To evaluate the clinical effectiveness and safety of pars plana vitrectomy with the inverted internal limiting membrane flap technique versus pars plana vitrectomy with conventional internal limiting membrane peeling for treating large macular holes, including idiopathic, traumatic, and myopic macular holes. The Cochrane Eyes and Vision Information Specialist searched CENTRAL, MEDLINE, Embase, two other databases, and two trials registries on 12 December 2022. We included randomized controlled trials (RCTs) that evaluated PPV with ILM peeling versus PPV with inverted ILM flap for treatment of large MHs (with a basal diameter greater than 400 µm at the narrowest point measured by optical coherence tomography) of any type (idiopathic, traumatic, or myopic). We used standard methodological procedures expected by Cochrane and assessed the certainty of the body of evidence using GRADE. We included four RCTs (285 eyes of 275 participants; range per study 24 to 91 eyes). Most participants were women (63%), and of older age (range of means 59.4 to 66 years). Three RCTs were single-center trials, and the same surgeon performed all surgeries in two RCTs (the third single-center RCT did not report the number of surgeons). One RCT was a multicenter trial (three sites), and four surgeons performed all surgeries. Two RCTs took place in India, one in Poland, and one in Mexico. Maximum follow-up ranged from three months (2 RCTs) to 12 months (1 RCT). No RCTs reported conflicts of interest or disclosed financial support. All four RCTs enrolled people with large idiopathic MHs and compared conventional PPV with ILM peeling versus PPV with inverted ILM flap techniques. Variations in technique across the four RCTs were minimal. There was some heterogeneity in interventions: in two RCTs, all participants underwent combined cataract-PPV surgery, whereas in one RCT, some participants underwent cataract surgery after PPV (the fourth RCT did not mention cataract surgery). The critical outcomes for this review were mean best-corrected visual acuity (BCVA) and MH closure rates. All four RCTs provided data for meta-analyses of both critical outcomes. We assessed the risk of bias for both outcomes using the Cochrane risk of bias tool (RoB 2); there were some concerns for risk of bias associated with lack of masking of outcome assessors and selective reporting of outcomes in all RCTs. All RCTs reported postoperative BCVA values; only one RCT reported the change in BCVA from baseline. Based on evidence from the four RCTs, it is unclear if the inverted ILM flap technique compared with ILM peeling reduces (improves) postoperative BCVA measured on a logarithm of the minimum angle of resolution (logMAR) chart at one month (mean difference [MD] -0.08 logMAR, 95% confidence interval [CI] -0.20 to 0.05; P = 0.23, I We found low-certainty evidence from four small RCTs that PPV with the inverted ILM flap technique is superior to PPV with ILM peeling with respect to BCVA gains at three or more months after surgery. We also found moderate-certainty evidence that the inverted ILM flap technique achieves more overall and type 1 MH closures. There is a need for high-quality multicenter RCTs to ascertain whether the inverted ILM flap technique is superior to ILM peeling with regard to anatomical and functional outcomes. Investigators should use the standard logMAR charts when measuring BCVA to facilitate comparison across trials.

Sections du résumé

BACKGROUND
Macular hole (MH) is a full-thickness defect in the central portion of the retina that causes loss of central vision. According to the usual definition, a large MH has a diameter greater than 400 µm at the narrowest point. For closure of MH, there is evidence that pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling achieves better anatomical outcomes than standard PPV. PPV with ILM peeling is currently the standard of care for MH management; however, the failure rate of this technique is higher for large MHs than for smaller MHs. Some studies have shown that the inverted ILM flap technique is superior to conventional ILM peeling for the management of large MHs.
OBJECTIVES
To evaluate the clinical effectiveness and safety of pars plana vitrectomy with the inverted internal limiting membrane flap technique versus pars plana vitrectomy with conventional internal limiting membrane peeling for treating large macular holes, including idiopathic, traumatic, and myopic macular holes.
SEARCH METHODS
The Cochrane Eyes and Vision Information Specialist searched CENTRAL, MEDLINE, Embase, two other databases, and two trials registries on 12 December 2022.
SELECTION CRITERIA
We included randomized controlled trials (RCTs) that evaluated PPV with ILM peeling versus PPV with inverted ILM flap for treatment of large MHs (with a basal diameter greater than 400 µm at the narrowest point measured by optical coherence tomography) of any type (idiopathic, traumatic, or myopic).
DATA COLLECTION AND ANALYSIS
We used standard methodological procedures expected by Cochrane and assessed the certainty of the body of evidence using GRADE.
MAIN RESULTS
We included four RCTs (285 eyes of 275 participants; range per study 24 to 91 eyes). Most participants were women (63%), and of older age (range of means 59.4 to 66 years). Three RCTs were single-center trials, and the same surgeon performed all surgeries in two RCTs (the third single-center RCT did not report the number of surgeons). One RCT was a multicenter trial (three sites), and four surgeons performed all surgeries. Two RCTs took place in India, one in Poland, and one in Mexico. Maximum follow-up ranged from three months (2 RCTs) to 12 months (1 RCT). No RCTs reported conflicts of interest or disclosed financial support. All four RCTs enrolled people with large idiopathic MHs and compared conventional PPV with ILM peeling versus PPV with inverted ILM flap techniques. Variations in technique across the four RCTs were minimal. There was some heterogeneity in interventions: in two RCTs, all participants underwent combined cataract-PPV surgery, whereas in one RCT, some participants underwent cataract surgery after PPV (the fourth RCT did not mention cataract surgery). The critical outcomes for this review were mean best-corrected visual acuity (BCVA) and MH closure rates. All four RCTs provided data for meta-analyses of both critical outcomes. We assessed the risk of bias for both outcomes using the Cochrane risk of bias tool (RoB 2); there were some concerns for risk of bias associated with lack of masking of outcome assessors and selective reporting of outcomes in all RCTs. All RCTs reported postoperative BCVA values; only one RCT reported the change in BCVA from baseline. Based on evidence from the four RCTs, it is unclear if the inverted ILM flap technique compared with ILM peeling reduces (improves) postoperative BCVA measured on a logarithm of the minimum angle of resolution (logMAR) chart at one month (mean difference [MD] -0.08 logMAR, 95% confidence interval [CI] -0.20 to 0.05; P = 0.23, I
AUTHORS' CONCLUSIONS
We found low-certainty evidence from four small RCTs that PPV with the inverted ILM flap technique is superior to PPV with ILM peeling with respect to BCVA gains at three or more months after surgery. We also found moderate-certainty evidence that the inverted ILM flap technique achieves more overall and type 1 MH closures. There is a need for high-quality multicenter RCTs to ascertain whether the inverted ILM flap technique is superior to ILM peeling with regard to anatomical and functional outcomes. Investigators should use the standard logMAR charts when measuring BCVA to facilitate comparison across trials.

Identifiants

pubmed: 37548231
doi: 10.1002/14651858.CD015031.pub2
pmc: PMC10558045
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD015031

Subventions

Organisme : NEI NIH HHS
ID : UG1 EY020522
Pays : United States

Informations de copyright

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4847-4855
pubmed: 28973331
Ophthalmology. 1996 Nov;103(11):1721-6
pubmed: 8942862
Ophthalmology. 2010 Oct;117(10):2018-25
pubmed: 20541263
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
J Ophthalmol. 2019 May 07;2019:6723824
pubmed: 31205783
Arch Ophthalmol. 1997 Jan;115(1):11-21
pubmed: 9006420
Ophthalmology. 1997 Jun;104(6):1033-40
pubmed: 9186446
J Med Libr Assoc. 2006 Apr;94(2):130-6
pubmed: 16636704
Ophthalmol Retina. 2023 Mar;7(3):227-235
pubmed: 36109006
J Ophthalmol. 2015;2015:939748
pubmed: 26425355
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Ophthalmic Surg Lasers Imaging Retina. 2018 Apr 1;49(4):236-240
pubmed: 29664979
Retina. 2011 Jan;31(1):127-47
pubmed: 21187734
JAMA Ophthalmol. 2017 Apr 1;135(4):299-305
pubmed: 28208188
Retina. 2015 Sep;35(9):1844-50
pubmed: 25946691
Indian J Ophthalmol. 2020 May;68(5):880-884
pubmed: 32317470
Retina. 2012 May;32(5):877-91
pubmed: 22105502
BMC Ophthalmol. 2021 Apr 10;21(1):174
pubmed: 33838649
Retina. 2019 Aug;39(8):1470-1477
pubmed: 29863535
Retina. 2017 Nov;37(11):2138-2144
pubmed: 28129215
Arch Ophthalmol. 2002 Jan;120(1):29-35
pubmed: 11786054
Indian J Ophthalmol. 2022 Mar;70(3):909-913
pubmed: 35225542
Ophthalmic Surg Lasers Imaging Retina. 2014 Mar-Apr;45(2):92-6
pubmed: 24635150
Ophthalmology. 1998 Oct;105(10):1835-8
pubmed: 9787352
Acta Ophthalmol. 2019 Jun;97(4):364-371
pubmed: 30242982
BMC Ophthalmol. 2018 Jul 20;18(1):177
pubmed: 30029621
Arch Ophthalmol. 1988 May;106(5):629-39
pubmed: 3358729
Klin Monbl Augenheilkd. 2010 Mar;227(3):175-80
pubmed: 20234979
Eur J Ophthalmol. 2018 May;28(3):324-328
pubmed: 28967075
Ophthalmology. 2014 Mar;121(3):649-55
pubmed: 24314837
BMC Ophthalmol. 2020 Jan 8;20(1):14
pubmed: 31914954
Ophthalmic Surg Lasers Imaging Retina. 2020 Mar 1;51(3):187-A2
pubmed: 32211909
Retina. 2018 May;38(5):870-882
pubmed: 29210940
Diagnostics (Basel). 2021 Jun 03;11(6):
pubmed: 34205224
Acta Ophthalmol Scand. 2002 Dec;80(6):579-87
pubmed: 12485276
Ophthalmology. 2013 Dec;120(12):2611-2619
pubmed: 24053995
Ophthalmology. 1988 Jul;95(7):917-24
pubmed: 3174041
J Ophthalmol. 2019 Mar 19;2019:5837832
pubmed: 31016038
Clin Exp Ophthalmol. 2008 Apr;36(3):257-60
pubmed: 18412595
Retina. 2017 Oct;37(10):1923-1930
pubmed: 28067723
Sci Rep. 2020 Sep 28;10(1):15832
pubmed: 32985592
PLoS One. 2020 Jul 24;15(7):e0236431
pubmed: 32706833
Graefes Arch Clin Exp Ophthalmol. 1996 Apr;234(4):241-5
pubmed: 8964529
BMJ. 1996 Nov 9;313(7066):1200
pubmed: 8916759
Ophthalmic Res. 2021;64(5):713-722
pubmed: 33596577
Eye (Lond). 2021 Oct;35(10):2746-2753
pubmed: 33235343
Retina. 2003 Jun;23(3):421-4
pubmed: 12824853
Graefes Arch Clin Exp Ophthalmol. 2018 Jun;256(6):1041-1049
pubmed: 29532170
Int J Retina Vitreous. 2018 Feb 19;4:8
pubmed: 29479478
Ophthalmology. 2009 Jul;116(7):1366-9
pubmed: 19576500
Ophthalmologica. 2020;243(5):334-341
pubmed: 31940651
Cochrane Database Syst Rev. 2023 Aug 7;8:CD015031
pubmed: 37548231
Br J Ophthalmol. 2001 Jan;85(1):102-8
pubmed: 11133724

Auteurs

Hashem Ghoraba (H)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Thanitsara Rittiphairoj (T)

Department of Ophthalmology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA.

Amir Akhavanrezayat (A)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Irmak Karaca (I)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Wataru Matsumiya (W)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Brandon Pham (B)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Kapil Mishra (K)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Cigdem Yasar (C)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Azadeh Mobasserian (A)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Amira Ahmed Abdelkarem (AA)

Public Health and Community Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Quan Dong Nguyen (QD)

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH